Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study
By Stephen Nakrosis
Alamar Biosciences said it would use its Nulisa platform to collaborate with GSK to study circulating protein signatures and disease progression.
The study will examine how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions, Alamar said.
The collaboration intends to generate insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings, the company added.
The study will analyze over 60,000 serum samples, using the Nulisaseq Immune 340 and Nulisaseq Neuro 220 panels. Many diseases that share a clinical diagnosis encompass biologically distinct patient populations, which contributes to differences in disease progression and treatment response, Alamar said.
The profiling is designed to generate a deep biomarker dataset spanning disease areas where non-uniform elements have historically made therapeutic development difficult, according to the company.
Alamar also said its platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, among other features.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 03, 2026 18:36 ET (23:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States